These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27324769)

  • 1. Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.
    Yu X; Wang G; Chen S; Wei G; Shang Y; Dong L; Schön T; Moradigaravand D; Parkhill J; Peacock SJ; Köser CU; Huang H
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5232-7. PubMed ID: 27324769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
    Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
    J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Tudó G; Lopez-Gavin A; Portell-Buj E; Freixes J; Vila J; Roman A; Monté MR; Gonzalez-Martin J
    Microb Drug Resist; 2020 Sep; 26(9):1019-1022. PubMed ID: 32159449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
    Disratthakit A; Prammananan T; Tribuddharat C; Thaipisuttikul I; Doi N; Leechawengwongs M; Chaiprasert A
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5189-97. PubMed ID: 27297489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.
    Willby M; Sikes RD; Malik S; Metchock B; Posey JE
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5427-34. PubMed ID: 26100699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Induction in vitro and stability of Mycobacterium tuberculosis resistance to ofloxacin].
    Yang H; Hu Z; Sha W; Lu J; Cui Z; Wang J; Huang X; Xiao H
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Apr; 48(4):318-23. PubMed ID: 24969458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.
    Chien JY; Chiu WY; Chien ST; Chiang CJ; Yu CJ; Hsueh PR
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2090-6. PubMed ID: 26787695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New generation fluoroquinolone sitafloxacin could potentially overcome the majority levofloxacin and moxifloxacin resistance in multidrug-resistant
    Sun Q; Cheng K; Liao X; Zhao W; Wang C; Wang C; Yan J; Dong L; Wang F; Jiang G; Huang H; Guo Z; Wang G
    J Med Microbiol; 2024 Jul; 73(7):. PubMed ID: 39028256
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.
    Singh P; Jain A; Dixit P; Prakash S; Jaiswal I; Venkatesh V; Singh M
    J Antibiot (Tokyo); 2015 Jan; 68(1):63-6. PubMed ID: 25052485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.
    Angeby KA; Jureen P; Giske CG; Chryssanthou E; Sturegård E; Nordvall M; Johansson AG; Werngren J; Kahlmeter G; Hoffner SE; Schön T
    J Antimicrob Chemother; 2010 May; 65(5):946-52. PubMed ID: 20332195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis.
    Qiao M; Ren W; Guo H; Huo F; Shang Y; Wang Y; Gao M; Pang Y
    Int J Infect Dis; 2021 May; 106():295-299. PubMed ID: 33864922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.
    Sayadi M; Zare H; Jamedar SA; Hashemy SI; Meshkat Z; Soleimanpour S; Hoffner S; Ghazvini K
    BMC Infect Dis; 2020 Jun; 20(1):390. PubMed ID: 32487030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.
    Kambli P; Ajbani K; Sadani M; Nikam C; Shetty A; Udwadia Z; Rodwell TC; Catanzaro A; Rodrigues C
    Tuberculosis (Edinb); 2015 Mar; 95(2):137-41. PubMed ID: 25522842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response.
    Seifert M; Capparelli E; Catanzaro DG; Rodwell TC
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.
    Fillion A; Aubry A; Brossier F; Chauffour A; Jarlier V; Veziris N
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4496-500. PubMed ID: 23836169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China.
    Zhang Z; Lu J; Wang Y; Pang Y; Zhao Y
    Antimicrob Agents Chemother; 2014; 58(1):364-9. PubMed ID: 24165186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific gyrA Gene Mutations Correlate with High Prevalence of Discordant Levofloxacin Resistance in Mycobacterium tuberculosis Isolates from Beijing, China.
    Huo F; Ma Y; Li S; Xue Y; Shang Y; Dong L; Li Y; Pang Y
    J Mol Diagn; 2020 Sep; 22(9):1199-1204. PubMed ID: 32619641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.
    Sirgel FA; Warren RM; Streicher EM; Victor TC; van Helden PD; Böttger EC
    J Antimicrob Chemother; 2012 May; 67(5):1088-93. PubMed ID: 22357804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.
    Cheng AF; Yew WW; Chan EW; Chin ML; Hui MM; Chan RC
    Antimicrob Agents Chemother; 2004 Feb; 48(2):596-601. PubMed ID: 14742214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased prevalence of levofloxacin-resistant Mycobacterium tuberculosis in China is associated with specific mutations within the gyrA gene.
    Huo F; Zhang F; Xue Y; Shang Y; Liang Q; Ma Y; Li Y; Zhao L; Pang Y
    Int J Infect Dis; 2020 Mar; 92():241-246. PubMed ID: 31978580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.